Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
11,688
Total Claims
$14.5M
Drug Cost
1,077
Beneficiaries
$13K
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 5,101 Rheumatology providers
-86%
Opioid rate vs peers
0.6% vs 4.1% avg
+123%
Cost per patient vs peers
$13K vs $6,039 avg
+103%
Brand preference vs peers
15.4% vs 7.6% avg
Opioid Prescribing
0.6%
Opioid Rate
67
Opioid Claims
$788
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,794 claims · $14.2M
Generic: 9,871 claims · $294K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Adalimumab | 519 | $4.0M |
| Upadacitinib | 330 | $2.2M |
| Etanercept | 198 | $1.5M |
| Corticotropin | 15 | $1.4M |
| Etanercept | 125 | $996K |
| Guselkumab | 45 | $632K |
| Abatacept | 108 | $626K |
| Certolizumab Pegol | 55 | $414K |
| Tofacitinib Citrate | 65 | $393K |
| Secukinumab | 39 | $376K |
| Adalimumab | 34 | $298K |
| Belimumab | 50 | $295K |
| Adalimumab | 31 | $237K |
| Apremilast | 34 | $169K |
| Leflunomide | 921 | $87K |
Prescribing Profile
Patient Profile
66
Avg Age
76%
Female
1.63
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About